IP Library › Granted Patent US 12686684
Granted Patent B2
US 12686684 · App. 19/344,450 · Granted Jul 21, 2026

BTK degrader and use thereof

Inventors: Jiantao Hu (Suzhou, CN); Jianyong Chen (Suzhou, CN)
Assignees: Ascentage Pharma (Suzhou) Co., Ltd.; Ascentage Pharma Group Corp Limited
C07D487/04A61K31/513A61K31/519A61P35/00C07D413/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12686684
App. No.
19/344,450
Granted
Jul 21, 2026
Kind
B2
Abstract

The present disclosure relates to compounds that function as degraders or inhibitors of BTK. The present disclosure further relates to pharmaceutical compositions comprising them, and to their use in the treatment of diseases mediated by BTK, such as cancer.

Claims (50)

1 . A compound selected from

and pharmaceutically acceptable salts and solvates thereof.

2 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

3 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

4 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

5 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

6 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

7 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

8 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

9 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

10 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

11 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

12 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

13 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

14 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

15 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

16 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

17 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

18 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

19 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

20 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

21 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

22 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

23 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

24 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

25 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

26 . A method for inhibiting and/or degrading BTK comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the compound of claim 1 .